Traws Pharma, Inc. (ticker: TRAW) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of TRAW's SEC filings surfaces 4 active risk signals, including 2 late-filing signals, 1 auditor-change signal, and 1 delisting/deregistration signal. TRAW reported $2.79M in revenue and $9.17M for the period ending 2025-12-31, with operating cash flow of -$18.18M. Cash and equivalents stood at $3.82M (down 82.1% year-over-year). Total assets of $10.62M are exceeded by total liabilities of $11.25M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
TRAW SEC Filings
Full cached SEC EDGAR filing history for TRAW, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.